Related Experiment Video
Updated: Jun 18, 2025
Use of Human Perivascular Stem Cells for Bone Regeneration
Published on: May 25, 2012
Zoledronic Acid and Enriched Autologous Bone Marrow Stem Cell Implantation for Femoral Head Osteonecrosis
Xuedong Li1, Huiling Tian2, Jingyi Zhang1
1Zhengzhou Orthopaedic Hospital, Longhai Middle Road 58, Zhengzhou, 450000 Henan China.
Purpose:
This study evaluated the clinical results of zoledronic acid in the treatment of early osteonecrosis of the femoral head (ONFH).
Materials And Methods:
Study retrospectively analyzed 60 patients with zoledronic acid with bone marrow stem cell (BMSC) implantation (The study group) and 64 patients with BMSC implantation (The control group). The primary evaluation index included VAS, HHS, collapsed rate, and total hip replacement arthroplasty (THA) conversion rate.
Results:
The study group had a lower VAS (1.12 ± 0.22 vs 1.44 ± 0.32) and higher HHS (75.07 ± 3.66 vs 68.78 ± 2.24) compared to the control group in 6 months after surgery (P < 0.05). In the study group, 12 hips (20%) collapsed, and 7 of 60 hips (11.67%) required THA surgery at the last follow-up. However, 25 hips (38.8%) collapsed in the control group, and 19 hips (29.69%) required THA surgery. The study group had a lower collapsed rate (P = 0.029) and THA conversion rate (P = 0.016) in survival analysis.
Conclusion:
Zoledronic acid and BMSC implantation in the treatment of early ONFH is safe and effective, reduces pain shortens recovery time, and reduces collapsed rate and THA conversion rate in ONFH patients.
